The Global Liquid Biopsy Market is expected to increase at a CAGR of 24.3% in the forecast period of 2017-2022 and reach a value of USD 2176.5 million by 2022 from USD 733.5 million in 2017.

This technology of liquid biopsy has enormous diagnostic and treatment implications for oncology and it is believed to transform clinical practice. A liquid biopsy, may capture the entire heterogeneity of the disease. This methodology is advantageous over tissue biopsies as monitoring of tumour genomic can be done by taking serial samples.

Foremost drivers for the liquid biopsy market include. Liquid biopsies are adopted due to the factors such as tolerability and patient convenience. Tissue biopsies cannot be done for few non-small cell lung cancers and liquid biopsy procedures are replacing tissue diagnosis procedures in such cases. Liquid biopsy research process involves a large amount of money and frequent clinical trials which is acting as a restraint for the market growth.

Explore More Information about report @ https://www.marketdataforecast.com/market-reports/global-liquid-biopsy-market-950/

The liquid biopsy market is mainly segmented by types of cancer into Lung Cancer, Pancreatic Cancer, Leukemia and Other Visceral Cancers. By Diagnostic approach they can be classified as Circulating Tumour cells (CTC), Circulating Tumour DNA (ctDNA), RNA in exosomes and Extra-Cellular Vesicles. Based on end users, the market is segmented into reference laboratories, hospital/physician laboratories, academic and research centers, and other end users. The market is bifurcate into blood, urine, plasma, saliva and Cerebrospinal fluid based upon sample type. CTCs (Circulating Tumour cells), the first such entities on the liquid biopsy scene, have accounted for a large share in the market. Cancer institute is the largest end user segment in terms of revenues and is expected to create substantial opportunity in global liquid biopsy market over the forecast period.

Geographically the market is segmented into North America (U.S.A. and Canada), Europe (U.K., Germany, Italy, France, and Spain), Asia-Pacific (India, China, Australia, South Korea and Japan), Latin America (Mexico, Argentina and Brazil), Middle East and Africa. All major action in the field of liquid biopsy is expected to emerge from North America and Europe region over the forecast period. However, increasing funding for private public partnerships in field of cancer research is expected to fuel the Asia-Pacific Market.

The key players dominating the liquid biopsy market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.

Request free sample @ https://www.marketdataforecast.com/market-reports/global-liquid-biopsy-market-950/request-sample

About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillsets dedicatedly serve clients from various industries and regions.

Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: [email protected]
Visit Market Data Forecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases